Picture of Biodexa Pharmaceuticals logo

BDRX Biodexa Pharmaceuticals Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Annual cashflow statement for Biodexa Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARS20-F20-F
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-5.46-7.66-7.08-5.73-6.38
Depreciation
Amortisation
Non-Cash Items-1.49-0.933-0.826-3.18-1.82
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital0.541.20.796-3.612.42
Change in Accounts Receivable
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-6.01-7.05-6.83-12.3-5.59
Capital Expenditures-0.32-0.062-0.263-0.774-0.691
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0.042-0.158-0.0020.1760.108
Acquisition of Business
Sale of Fixed Assets
Other Investing Cash Flow
Cash from Investing Activities-0.278-0.22-0.265-0.598-0.583
Financing Cash Flow Items-0.015-0.018-0.013-0.014
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities8.80.04710.28.5613
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash2.51-7.223.13-4.36.87